Progression of alloresponse and tissue-specific immunity during graft coronary artery disease

American Journal of Transplantation

Volumn 5, Issue 6, 2005, Pages 1286-1296

  Tanaka, Masashi ^a   Zwierzchoniewska, Monika ^a   Mokhtari, Golnaz K ^a   Terry, Raya D ^a   Balsam, Leora B ^a   Robbins, Robert C ^a   Fedoseyeva, Eugenia V ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac myocin; Graft coronary artery disease; Indirect alloresponse; Minor histocompatibility complex; Tissue specific autoimmunity

Indexed keywords

AUTOANTIBODY; CARDIAC MYOSIN; HEART ANTIGEN; IMMUNOGLOBULIN G1 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNE RESPONSE; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PATHOGENESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; T LYMPHOCYTE ACTIVATION; TISSUE SPECIFICITY;

ANIMALS; ANTIBODY FORMATION; AUTOIMMUNITY; CARDIAC MYOSINS; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNE TOLERANCE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 20544434923     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00880.x     Document Type: Article

References (50)

1. Taylor DO, Edwards LB, Mohacsi PJ et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report-2003. J Heart Lung Transplant 2003; 22: 616-624.
2. Tanaka M, Fedoseyeva EV, Bobbins RC. Graft coronary artery disease in murine cardiac allografts: proposal to meet the need for standardized assessment. J Heart Lung Transplant 2005; 24: 316-322.
3. Massicot-Fisher J, Noel P, Madsen JC. Recommendations of the National Heart, Lung and Blood Institute Heart and Lung Tolerance Working Group. Transplantation 2001; 72: 1467-1470.
4. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387-397.
5. Valentine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation 2003; 76: 891-899.
6. Waaga AM, Gasser M, Laskowski I, Tilney NL. Mechanisms of chronic rejection. Curr Opin Immunol 2000; 12: 517-521.
7. Paul LC. Immunologic risk factors for chronic renal allograft dysfunction. Transplantation 2001; 71: SS17-SS23.
8. Liu Z, Colovai AI, Tugulea S et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996; 98: 1150-1157.
9. Vella JP, Magee C, Vos L et al. Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Transplantation 1999; 67: 1523-1532.
10. SivaSai KS, Smith MA, Poindexter NJ et al. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999; 67: 1094-1098.
11. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001; 167: 7199-7206.
12. Lee RS, Yamada K, Houser SL et al. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. Proc Natl Acad Sci U S A 2001; 98: 3276-3281.
13. Ensminger SM, Witzke O, Spriewald BM et al. CD8+ T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation 2000; 69: 2609-2612.
14. Yasufuku K, Heidler KM, Woods KA et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 2002; 73: 500-505.
15. Rolls HK, Kishimoto K, Dong V et al. T cell response to cardiac myosin persists in the absence oa an alloimmune response in recipients with chronic cardiac allograft rejection. Transplantation 2002; 74: 1053-1057.
16. Joosten SA, van Dixhoorn MG, Borrias MC et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002; 160: 1301-1310.
17. Jurcevic S, Ainsworth ME, Pomerance A et al. Antivimentin antibodies are an independent predictor of transplant- associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886-892.
18. Bates RL, Frampton G, Rose ML, Murphy JH. High diversity of non-human leukocyte antigens in transplant-associated coronary artery disease. Transplantation 2003; 75: 1347-1350.
19. Fernandez FG, Jaramillo A, Cher C et al. Airway epithelium is the primary target of allograft rejection in murine obliterative airway disease. Am J Transplant 2004; 4: 319-325.
20. Wu GD, Jin YS, Salazar R et al. Vascular endothelial cell apoptosis induced by anti-donor non-MHC antibodies: a possible injury pathway contributing to chronic allograft rejection. J Heart Lung Transplant 2002; 21: 1174-1187.
21. Derhaag JG, Duijvestijn AM, Damoiseaux JG, van Breda Vriesman PJ. Effects of antibody reactivity to major histocompatibility complex (MHC) and non-MHC alloantigens on graft endothelial cells in heart allograft rejection. Transplantation 2000; 69: 1899-1906.
22. Russell PS, Chase CM, Colvin RB. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 1997; 64: 1531-1536.
23. Fedoseyeva EV, Zhang F, Orr PL, Levin D, Buncke HJ, Benichou G. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol 1999; 162: 6836-6842.
24. Rose NR, Neumann DA, Herskowitz A. Autoimmune myocarditis: concepts and questions. Immunol Today 1991; 12: 253-255.
25. Fedoseyeva EV, Kishimoto K, Rolls HK et al. Modulation of tissue-specific immune response to cardiac myosin can prolong survival of allogeneic heart transplants. J Immunol 2002; 169: 1168-1174.
26. Li XC, Zand MS, Li Y, Zheng XX, Strom TB. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J Immunol 1998; 161: 2241-2247.
27. Sano Y, Streilein JW, Ksander BR. Detection of minor alloantigen-specific cytotoxic T cells after rejection of murine orthotopic corneal allografts: evidence that graft antigens are recognized exclusively via the "indirect pathway". Transplantation 1999; 68: 963-970.
28. Valujskikh A, Matesic D, Heeger PS. Characterization and manipulation of T cell immunity to skin grafts expressing a transgenic minor antigen. Transplantation 1999; 68: 1029-1036.
29. Chen Y, Demir Y, Valujskikh A, Heeger PS. The male minor transplantation antigen preferentially activates recipient CD4+ T cells through the indirect presentation pathway in vivo. J Immunol 2003; 171: 6510-6518.
30. Sahara H, Shastri N. Second class minors: molecular identification of the autosomal H46 histocompatibility locus as a peptide presented by major histocompatibility complex class II molecules. J Exp Med 2003; 197: 375-385.
31. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343-350.
32. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162: 352-358.
33. Shiverick KT, Thomas LL, Alpert NR. Purification of cardiac myosin. Application to hypertrophied myocardium. Biochim Biophys Acta 1975; 393: 124-133.
34. Shenton BK, Bal W, Bell AE, Bookless B, Corris P, Dark DH. The value of flow cytometric crossmatch in cardiac transplantation. Transpl Int 1994; 7: S359-S362.
35. Krasinskas AM, Eiref SD, McLean AD et al. Replacement of graft-resident donor-type antigen presenting cells alters the tempo and pathogenesis of murine cardiac allograft rejection. Transplantation 2000; 70: 514-521.
36. Illigens BM, Yamada A, Fedoseyeva EV et al. The relative contribution of direct and indirect antigen recofnition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol 2002; 63: 912-925.
37. Mosmann TR, Coffman RL. TH1 and TH2: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7: 145-173.
38. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts II. Importance of humoral immunity. J Immunol 1994; 152: 5135-5141.
39. VanBuskirk AM, Wakely ME, Sirak JH, Orosz CG. Patterns of allosensitization in allograft recipients: long-term allograft acceptance is associated with active alloantibody production in conjunction with active inhibition of alloreactive delayed-type hypersensitivity. Transplantation 1998; 65: 1115-1123.
40. Pelletier RP, Hennessy PK, Adams PW, VanBuskirk AM, Ferguson RM, Orosz CG. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002; 2: 134-141.
41. Michaels PJ, Espejo ML, Kobashigawa J et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences, and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58-69.
42. Forbes RD, Zheng SX, Gomersall M, Guttmann RD. Irreversible chronic vascular rejection occurs only after development of advanced allograft vasculopathy: a comparative study of a rat cardiac allograft model using a retransplantation protocol. Transplantation 1997; 63: 743-749.
43. Poston RS, Billingham M, Hoyt EG et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999; 100: 67-74.
44. Qian Z, Hu W, Liu J, Sanfillipo F, Hruban RH, Baldwinn WMI. Accelerated graft arteriosclerosis in cardiac transplants. Complement activation promotes progression of lesions from medium to large arteries. Transplantation 2001; 72: 900-906.
45. Rose ML, Smith JD, Lawson C. Antibody formation and its impact on long-term graft outcome. Transpl Proc 2001; 33: 2411-2413.
46. Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology: the immune system in health and disease. 5th Ed. New York: Garland Publishing, 2001.
47. Lee RS, Grusby MJ, Glimcher LH, Winn HJ, Auchincloss H, Jr. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994; 179: 865-872.
48. Forsthuber T, Yip HC, Lehmann PV. Induction of Th1 and Th2 immunity in neonatal mice. Science 1996; 271: 1728-1730.
49. Liao L, Sindhwani R, Leinwand L, Diamond B, Factor S. Cardiac alpha-myosin heavy chains differ in their induction of myocarditis. Identification of pathogenic epitopes. J Clin Invest 1993; 92: 2877-2882.
50. Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwinn WMI, Wasowska BA. Non-complement and complement-activating antibodies synergize to cause rejection of cardiac transplants. Am J Transplant 2004; 4: 326-334.